Reimbursement May Be a Hurdle to Success for Med-Tech Companies
Brian Marckx, CFA, is Director of Research and Senior MedTech Analyst at Zacks Investment Research. Prior to joining Zacks, Mr. Marckx worked as a high yield bond analyst on Wachovia Securities’ institutional trading desks where he specialized in the health care and industrials industries. Prior to that, he was an analyst in corporate finance at First Union National Bank. Mr. Marckx has covered the medical device, pharmaceutical and biotechnology industries since joining Zacks in 2007. Brian Marckx has been quoted in numerous publications, including The Wall Street Journal, Barron's, Bloomberg Businessweek and Kiplinger. His work has also been cited in various market studies and working papers, including those from Massachusetts Institute of Technology, Deloitte & Touche and Pharmaceutical Manufacturing. Mr. Marckx graduated with a B.S. in finance from St. John Fisher College and received his MBA from Wake Forest University. Brian Marckx is a holder of the Chartered Financial Analyst — CFA — designation. Profile
Word count: 3,814
TWST: Provide, if you would, your overall outlook and the analysis behind it for the next 12 months for your coverage.